SCHEMBL2359249

SCHEMBL2359249

CC(=O)c1ccc(-c2sc(NC(=O)NCCc3cn(C(C)C)cn3)nc2C)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 15/20 0.48
PIK3CA P42336 12/20 0.48
PIK3CD O00329 10/20 0.48
PIK3CB P42338 8/20 0.48
PI4KB Q9UBF8 7/20 0.48
CLK2 P49760 2/20 0.48
CLK1 P49759 1/20 0.48
CYP2C9 P11712 1/20 0.43
PRKDC P78527 1/20 0.43
KCNH2 Q12809 1/20 0.43
DYRK3 O43781 2/20 0.39
MAP4K4 O95819 2/20 0.39
DYRK1A Q13627 1/20 0.39
MINK1 Q8N4C8 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
PIK3C2A O00443 1/20 0.35
PIK3C2B O00750 1/20 0.35
CDK9 P50750 1/20 0.35
MAP4K2 Q12851 1/20 0.35
STK17A Q9UEE5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1783963 0.87 PIK3CG (0.64) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2958630 0.87 PIK3CG (0.58) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2324076 0.83 PIK3CG (0.49) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL12991130 0.83 PIK3CG (0.53) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL1886949 0.83 PIK3CG (0.49) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2323047 0.82 PIK3CG (0.51) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2329878 0.81 PIK3CG (0.49) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2361231 0.80 PIK3CG (0.48) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2360347 0.78 PIK3CG (0.48) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2359167 0.77 PIK3CD (0.54) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2357179-A1 Thiazol-2-yl organic compounds Novartis AG (CH) 2011-08-17 EP claimed
US-7754746-B2 Organic compounds NOVARTIS AG (CH) 2010-07-13 US claimed
CN-101374823-A Organic compounds NOVARTIS AG (CH) 2009-02-25 CN claimed
US-20080319033-A1 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma NOVARTIS AG 2008-12-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319033-A1 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma AKT3, PIK3R3, PIK3CD PIK3CG 10/4885PIK3CA 4/4885PIK3CD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.